Yale Cancer Center | Strategic Alliance Partners

Yale Cancer Center (YCC) is one of only 56 National Cancer Institute-designated comprehensive cancer centers in the nation and the only such center in Connecticut. Cancer treatment for patients is available at Smilow Cancer Hospital through 13 multidisciplinary teams and at 15 Smilow Cancer Hospital Care Centers in Connecticut and Rhode Island. Comprehensive cancer centers play a vital role in the advancement of the NCI’s goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.

Latest from Yale Cancer Center

Yale Study: Potential Treatment Pathway Found for Rare and Aggressive Leukemia

September 09, 2025

Article

A Yale study published identified the mechanism underlying the relationship between the development of AMKL and a specific genetic alteration that occurs.

Cancer's Progress Detailed by 3D Genomic Maps

August 26, 2025

Article

New tool by Yale researchers charts journey from pre-cancerous to advanced disease in animal models.

Tailored Therapies Needed to Overcome Immune-Cold Microenvironment of Chromophobe RCC

August 15, 2025

Article

David A. Braun, MD, PhD, discusses the need for more tailored treatments that improve tumor-specific T-cell infiltration in chromophobe RCC.

Defects in Antitumor Immunity May Account for Limited Efficacy With Checkpoint Inhibition in Chromophobe RCC

August 14, 2025

Article

David A. Braun, MD, PhD, outlines differences in the tumor biology and immune phenotypes of chromophobe and clear cell renal cell carcinoma.

Chromophobe RCC Microenvironment Study Shows Determinants of Impaired Antitumor Immunity

August 08, 2025

Article

Although chromophobe RCC has an immune-cold environment, ferroptosis induction may be a promising target for managing tumor resistance in this subtype.

Yale Researchers Develop Novel Antibody-RNA Therapy for Resistant Cancers

July 23, 2025

Article

More than 2 dozen Yale experts are collaborating on a therapy for the most defended tumors.

AI Outperforms People in Scoring Melanoma Tumor-Infiltrating Immune Cells

July 16, 2025

Article

A Yale study found that open-source AI tools outperformed traditional, visual methods for measuring the abundance of melanoma biomarkers.

AI Tool Set to Transform Characterization and Treatment of Cancers

July 01, 2025

Article

A team of researchers at Yale developed and tested a new AI tool to help better characterize the diversity of individual tumor cells.

Dr Vasquez on the Rationale for Investigating NAMPT Inhibition in Rhabdomyosarcoma

June 30, 2025

Video

Juan Vasquez, MD, discussed unmet needs for patients with pediatric rhabdomyosarcoma that investigations of NAMPT inhibition may address.

Yale Announces New Biomedical Imaging Institute

June 25, 2025

Article

Yale School of Medicine announced the opening of the Yale Biomedical Imaging Institute, uniting imaging, clinical translation, and data science.

Dr Vasquez on NAPRT as a Potential Biomarker for NAMPT Inhibition in Pediatric Rhabdomyosarcoma

May 22, 2025

Video

Juan Vasquez, MD, discusses how loss of NAPRT expression may serve as a biomarker for antitumor activity with NAMPT inhibition in rhabdomyosarcoma.

Five Under 5: Top Oncology Videos for the Week of 5/4

May 11, 2025

Article

The top 5 OncLive videos of the week cover insights in myelodysplastic syndrome, lung cancer, hepatocellular carcinoma, colorectal cancer, and ovarian cancer.

Dr Zeidan on the Evaluation of Immunotherapy and Other Novel Therapies in MDS

May 08, 2025

Video

Amer Zeidan, MBBS, discusses completed and ongoing research evaluating immunotherapy and other novel agents in patients with myelodysplastic syndromes.

Dr Cecchini on the Efficacy of Neoadjuvant Chemotherapy in CRC Liver Metastases

April 29, 2025

Video

Michael Cecchini, MD, discusses the effects of neoadjuvant chemotherapy on tumor-infiltrating lymphocyte levels in colorectal cancer with liver metastases.

Radioligand Therapy Advances Represent the Future of mCRPC Treatment: With Daniel P. Petrylak, MD

April 24, 2025

Podcast

Daniel P. Petrylak, MD, discusses the role of Lutetium Lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer.

Deintensification of Treatment Modalities Is Crucial to Consider in Head and Neck Cancer

April 24, 2025

Article

Zafar Sayed, MD, explains advances in surgical head and neck cancer approaches, including the use of transoral robotic surgery.

Study Reveals Subgroups of Patients With RCC Who May Have Durable Responses to Immunotherapy: With David A. Braun, MD, PhD

March 27, 2025

Podcast

Dr Braun discusses molecular factors that contribute to exceptional immune checkpoint inhibition responses among patients with renal cell carcinoma.

Novel Curriculum Aims to Address Burnout and Foster Wellness Among Fellows

March 25, 2025

Article

Thejal Srikumar, MD, MPH, discusses the Yale School of Medicine's unique approach to offering fellows a space to address professional burnout.

Dr Oh on the Development of Targeted Therapies in Prostate Cancer

February 17, 2025

Video

William K. Oh, MD, highlights the evolution of targeted therapy for prostate cancer treatment, including antibody-drug conjugates and bispecific antibodies.

Oncology Experts Preview Top Abstracts From 2025 ASCO GU

February 12, 2025

Article

Experts highlight the top presentations to watch for at the 2025 Genitourinary Cancers Symposium.